MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

MDT

88.44

-0.16%↓

VEEV

284.2

+0.67%↑

A

121.49

+1.08%↑

WBA

11.47

-0.09%↓

HQY

101.96

+0.85%↑

Search

Supernus Pharmaceuticals Inc

Slēgts

SektorsVeselības aprūpe

31.9 0.03

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

31.62

Max

31.97

Galvenie mērījumi

By Trading Economics

Ienākumi

-27M

-12M

Pārdošana

-24M

150M

P/E

Sektora vidējais

28.396

40.527

Peļņas marža

-7.894

Darbinieki

674

EBITDA

-27M

18M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt

Prognoze 12 mēnešiem

+21.61% upside

Dividendes

By Dow Jones

Nākamie ieņēmumi

2025. g. 5. aug.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

-388M

1.8B

Iepriekšējā atvēršanas cena

31.87

Iepriekšējā slēgšanas cena

31.9

Ziņu noskaņojums

By Acuity

50%

50%

146 / 375 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Weak Bearish Evidence

Supernus Pharmaceuticals Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 4. jūl. 20:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2025. g. 4. jūl. 20:50 UTC

Tirgus saruna

Tech, Media & Telecom Roundup: Market Talk

2025. g. 4. jūl. 20:50 UTC

Tirgus saruna

Health Care Roundup: Market Talk

2025. g. 4. jūl. 20:50 UTC

Tirgus saruna

Energy & Utilities Roundup: Market Talk

2025. g. 4. jūl. 16:20 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2025. g. 4. jūl. 16:20 UTC

Tirgus saruna

Energy & Utilities Roundup: Market Talk

2025. g. 4. jūl. 16:20 UTC

Tirgus saruna

Tech, Media & Telecom Roundup: Market Talk

2025. g. 4. jūl. 16:20 UTC

Tirgus saruna

Health Care Roundup: Market Talk

2025. g. 4. jūl. 16:15 UTC

Tirgus saruna

Global Commodities Roundup: Market Talk

2025. g. 4. jūl. 15:57 UTC

Tirgus saruna

Base Metal Prices Fall in Thin, Risk-off Trading -- Market Talk

2025. g. 4. jūl. 15:49 UTC

Tirgus saruna

Gold Futures Set to End Week Flat After Mixed Jobs Report -- Market Talk

2025. g. 4. jūl. 15:49 UTC

Iegādes, apvienošanās, pārņemšana

Credit Agricole: Deal Will Have a Negative Impact of Approximately 30 Basis Points on the Fully-Loaded CET1 Ratio

2025. g. 4. jūl. 15:49 UTC

Iegādes, apvienošanās, pārņemšana

Credit Agricole: Transaction Is Consistent With Targets in Terms of Return of Investment, Return on Tangible Equity

2025. g. 4. jūl. 15:49 UTC

Iegādes, apvienošanās, pārņemšana

Credit Agricole Received All Required Authorizations

2025. g. 4. jūl. 15:48 UTC

Iegādes, apvienošanās, pārņemšana

Credit Agricole: CACEIS and Santander Are Maintaining Their Long-Term Partnership

2025. g. 4. jūl. 15:47 UTC

Iegādes, apvienošanās, pārņemšana

Credit Agricole: Agreement Was Announced on Dec. 19

2025. g. 4. jūl. 15:47 UTC

Iegādes, apvienošanās, pārņemšana

Credit Agricole Now Controls 100% of the Share Capital of CACEIS

2025. g. 4. jūl. 15:46 UTC

Iegādes, apvienošanās, pārņemšana

Credit Agricole Completes Acquisition of Santander's 30.5% Stake in CACEIS

2025. g. 4. jūl. 14:30 UTC

Iegādes, apvienošanās, pārņemšana

Rocky Shore Closes Hemlo Area Claims Sale to Barrick Mining Unit for C$975,000 Cash

2025. g. 4. jūl. 13:53 UTC

Tirgus saruna

Polish Zloty Faces Hit From Prospect of Further Rate Cuts -- Market Talk

2025. g. 4. jūl. 13:41 UTC

Tirgus saruna

Japanese Yen Could Receive Boost From Increased Rate-Hike Bets -- Market Talk

2025. g. 4. jūl. 13:41 UTC

Tirgus saruna

Market Talk Roundup: Latest on U.S. Politics

2025. g. 4. jūl. 13:15 UTC

Tirgus saruna

Global Commodities Roundup: Market Talk

2025. g. 4. jūl. 12:37 UTC

Tirgus saruna

Fund Manager Roundup: U.S. Treasurys in Focus Amid Rising Debt

2025. g. 4. jūl. 12:37 UTC

Tirgus saruna

Fund Manager Roundup: U.S. Treasurys in Focus -2-

2025. g. 4. jūl. 12:30 UTC

Tirgus saruna

Fund Manager Roundup: U.S. Tariff Deadline Key for Dollar Outlook, U.K. Fiscal Risks In Focus for Pound

2025. g. 4. jūl. 12:15 UTC

Tirgus saruna

Targeted Tariffs Would Likely Support Dollar -- Market Talk

2025. g. 4. jūl. 12:13 UTC

Tirgus saruna

Further Pause in Tariffs Would Have Unclear Impact on Dollar -- Market Talk

2025. g. 4. jūl. 12:02 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 4. jūl. 12:02 UTC

Tirgus saruna

Market Talk Roundup: Latest on U.S. Politics

Salīdzinājums

Cenas izmaiņa

Supernus Pharmaceuticals Inc Prognoze

Cenas mērķis

By TipRanks

21.61% augšup

Prognoze 12 mēnešiem

Vidējais 39 USD  21.61%

Augstākais 45 USD

Zemākais 36 USD

Pamatojoties uz 3 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Supernus Pharmaceuticals Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

3 ratings

1

Pirkt

2

Turēt

0

Pārdot

Tehniskais rādītājs

By Trading Central

31.35 / 32.36Atbalsts un pretestība

Īstermiņā

Weak Bearish Evidence

Vidējā termiņā

Bearish Evidence

Ilgtermiņā

Neutral Evidence

Noskaņojums

By Acuity

146 / 375 Rangs Veselības aprūpe

Ziņu noskaņojums

Neutral

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Virs vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Supernus Pharmaceuticals Inc

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age. It also offers comprise Qelbree, a novel non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, the company's product candidates include SPN-830, a late-stage drug/device combination product candidate for the treatment of off episodes in PD patients; SPN-817, a novel first-in-class selective acetylcholinesterase inhibitor, which is in Phase II clinical trials for the treatment of epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; SPN-443, a preclinical product for the treatment of ADHD/CNS; and SPN-446 for narcolepsy and SPN-448 for the treatment of CNS which is in discovery stage. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Rockville, Maryland.